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Abstract: Human cytomegalovirus (HCMV) is the major viral cause of congenital 
infection and birth defects. Primary maternal infection often results in virus transmission, 
and symptomatic babies can have permanent neurological deficiencies and deafness. 
Congenital infection can also lead to intrauterine growth restriction, a defect in placental 
transport. HCMV replicates in primary cytotrophoblasts (CTBs), the specialized cells of 
the placenta, and inhibits differentiation/invasion. Human trophoblast progenitor cells 
(TBPCs) give rise to the mature cell types of the chorionic villi, CTBs and multi-nucleated 
syncytiotrophoblasts (STBs). Here we report that TBPCs are fully permissive for 
pathogenic and attenuated HCMV strains. Studies with a mutant virus lacking a functional 
pentamer complex (gH/gL/pUL128-131A) showed that virion entry into TBPCs is 
independent of the pentamer. In addition, infection is blocked by a potent human 
neutralizing monoclonal antibody (mAb), TRL345, reactive with glycoprotein B (gB),  
but not mAbs to the pentamer proteins pUL130/pUL131A. Functional studies revealed that 
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neutralization of infection preserved the capacity of TBPCs to differentiate and assemble 
into trophospheres composed of CTBs and STBs in vitro. Our results indicate that mAbs to 
gB protect trophoblast progenitors of the placenta and could be included in antibody 
treatments developed to suppress congenital infection and prevent disease.  
Keywords: HCMV; congenital; trophoblast; progenitors; neutralizing; placenta; 
development; neutralization; pentamer; hyperimmune globulin 
 
1. Introduction 
Human cytomegalovirus (HCMV) is the major viral cause of congenital infections and affects 1%–3% 
of live births in the U.S. [1]. Virus transmission to the fetus occurs in 40%–50% of cases of primary 
infection and can result in birth defects, including severe neurological disorders, impaired hearing, 
vision loss and intrauterine growth restriction (IUGR), a defect that results from compromised 
placental function [2–4]. In contrast, due to immunity from maternal antibodies, recurrent infection is 
associated with a reduced viral transmission rate (0.1% to 2%) [5]. Although recent studies indicate 
that the frequency of hearing loss is similar in pregnancies complicated by primary and recurrent 
infection, the severity is greater in cases of primary infection [6,7]. 
Currently, there are no approved therapeutics for congenital HCMV infection in cases of primary 
maternal infection due to concerns over the toxicity and teratogenicity of available antiviral drugs 
(reviewed in [8,9]). A recently developed therapeutic approach is the administration of hyperimmune 
globulin (HIG), a pooled immunoglobulin preparation from donors with high-avidity anti-HCMV 
antibodies. In initial (non-randomized) clinical studies, treatment of pregnant women with HIG within 
4 to 6 weeks after seroconversion was found to improve fetal outcome [10–13]. Analysis of placentas 
revealed that viral replication was reduced and compensatory development enabled growth of 
chorionic villi increasing the placental surface perfused by maternal blood [12,14]. However, reported 
studies were small and the results should be confirmed by double-blinded clinical trials [15]. To date, 
administration of HIG has been approved by the Food and Drug Administration only for transplant 
recipients [16–18]. As promising novel therapeutics, human monoclonal antibodies (mAbs) specific 
for epitopes on HCMV proteins have been developed using technological advancement of human  
B-cell cloning from highly seropositive donors [19–23]. 
Chorionic villi, the functional units of the placenta, are composed of a stromal core that contains 
blood vessels continuous with the fetal vasculature. The core is surrounded by a basement membrane 
populated by villus cytotrophoblasts (vCTBs), covered by a multinucleated syncytiotrophoblast (STB) 
layer. At the tips of the villi, vCTBs differentiate and switch their adhesion phenotype to that of 
invasive cytotrophoblasts (iCTBs), which penetrate the decidua and remodel uterine arteries, providing 
maternal blood to the placenta [24,25]. STBs, which are bathed in maternal blood, mediate transport of 
nutrients and oxygen to the fetal bloodstream. In contrast to CTBs, whose proliferative potential is 
limited [26,27], trophoblast progenitor cells (TBPCs), resident in the chorion, proliferate and 
differentiate into the mature trophoblast populations [28]. 




Previous studies from our lab suggested that during the course of transmission, HCMV first 
replicates in uterine blood vessels, then spreads to differentiating iCTBs, where infection 
downregulates cell-matrix adhesion molecules and impairs cell differentiation/invasion [29–33]. 
Studies of congenital infection in placentas from early gestation and at term indicated a central role for 
high-avidity, neutralizing antibodies in suppression of infection [34–36]. We recently reported that 
some cases of IUGR have underlying primary or recurrent maternal infection, which impaired 
placental development [4]. In a case of IUGR associated with preterm delivery, chorionic villi 
contained unusual clusters of extravillous, cytokeratin 7 (CK7)-positive CTBs, suggesting arrested 
differentiation. In cases of symptomatic congenital infection, infected cell proteins were detected in 
TBPCs in the chorion, suggesting that virus replication could interfere with TBPC self-renewal and 
differentiation [37]. 
HCMV encodes several glycoprotein complexes in the virion envelope that function in attachment 
and penetration of host cells. A highly studied envelope protein important for virion entry into all cell 
types is gB [38,39]. gB facilitates attachment to the cell surface by binding to heparin sulfate 
glycosaminoglycans [40,41], cellular receptors [42,43] and integrins [44,45] and, in cooperation with 
gH/gL complexes, mediates membrane fusion [46]. In contrast to the fibroblast-adapted (attenuated) 
strains AD169 and Towne, clinical strains, such as VR1814 and TB40/E, are pathogenic and express 
the pentamer glycoprotein complex gH/gL/pUL128-131A, which is required for virus entry into 
epithelial and endothelial cells [47,48] but not fibroblasts [49,50]. AD169 and Towne have acquired 
mutations in the UL128-131A locus, lack a functional pentamer and are impaired in infection of 
epithelial and endothelial cells [51,52]. 
Recently, TBPCs were isolated from the chorions of human placentas, and lines of continuously 
self-renewing cells were established [27]. These TBPCs express the trophoblast marker CK7, factors 
for stem cell self-renewal, including HMGA2 (high-mobility group AT-hook 2), and proteins required 
for trophoblast fate specification, GATA-3, GATA-4, Eomes (Eomesodermin) and GCM-1 (glial cell 
missing homolog 1). When cultured under differentiation conditions, TBPCs aggregate and form 
spheres (trophospheres) that upregulate HLA-G, a marker of differentiating iCTBs, and increase 
expression of human placental lactogen and human chorionic gonadotropin (normally secreted from 
STBs) [27], in accord with differentiation in utero. 
Here, we have identified glycoproteins involved in entry of HCMV virions into TBPCs established 
from first and second trimester placentas and measured the extent to which neutralizing mAbs to gB 
and the pentameric complex block infection. We found that TBPCs are susceptible to infection with 
both the pathogenic VR1814 and the attenuated AD169 strain and that both strains undergo lytic viral 
replication in TBPCs. In addition, we found that virion entry into TBPCs was independent of the 
pentamer complex, as shown by infection with a UL131A-deficient mutant [53,54] and confirmed by 
failure of anti-pentamer mAbs to block VR1814 infection. Importantly, virion entry was found to 
depend on gB function. Consequently, neutralization of infection with an anti-gB mAb (TRL345) was 
found to preserve the ability of TBPCs to differentiate and form trophospheres. 
  




2. Results and Discussion 
2.1. TBPCs from First and Second Trimesters Are Permissive for Pathogenic and Attenuated  
HCMV Strains 
TBPC expression of markers for trophoblasts (CK7), stem cell self-renewal (HMGA2) and 
trophoblast fate acquisition (GATA-4 and GATA-3) was confirmed by immunostaining. Over 90% of 
TBPCs in culture expressed these markers (Figure 1). 
Figure 1. TBPCs express markers of trophoblasts and pluripotency. TBPCs from 7.3 weeks 
(left panel) and 15.6 weeks (right panel) of gestation were immunostained for CK7 (A, E), 
HMGA2 (B, F), GATA-4 (C, G) or GATA-3 (D, H). Nuclei were counterstained with 
DAPI. Scale bar = 100 µm.  
 
 
To determine whether TBPCs isolated from placentas at 7.3 and 15.6 weeks of gestation were 
susceptible to infection, suspensions of VR1814 and AD169 were adsorbed to TBPCs and the cells 
immunostained at the indicated time points for expression of immediate-early protein IE1, early 
proteins pUL112/pUL113 and late protein pp28. We found that viral proteins were expressed at 
comparable levels in VR1814- and AD169-infected cells (Figure 2), indicating that TBPCs were 
susceptible to lytic HCMV infection. In 15.6 weeks TBPCs, nearly all cells expressed IE1 in nuclei 
at 1 day post infection (dpi), and pUL112/pUL113 were detected at 2 dpi. pp28 was present in most 
cells at 4 dpi (Figure 2A) suggesting viral DNA replication [55]. In 7.3 weeks TBPCs, fewer cells 
expressed viral proteins. Approximately 70% expressed IE1 at 1 dpi and 85% at 4 dpi (Figure 2B). 
pUL112/pUL113 and pp28 were expressed in nearly all cells by 7 dpi, suggesting delayed viral gene 
expression. Nonetheless, almost all TBPCs from both gestational ages expressed late infected-cell 













proteins within a week. Altogether, our results indicate that first and second trimester TBPCs are 
permissive for pathogenic and attenuated virus strains. Because results for first and second trimester 
TBPCs were similar, only TBPCs from 15.6 weeks of gestation were used for subsequent experiments. 
Figure 2. VR1814 and AD169 replicate in TBPCs. Cells from 15.6 weeks (A)  
or 7.3 weeks (B) of gestation were infected (MOI 2) and immunostained for HCMV IE1, 
pUL112/pUL113 or pp28 at the indicated time points (green). Mock-infected controls  
were immunostained for CK7 (red). Nuclei were counterstained with DAPI (blue).  
Scale bar = 100 µm. 
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2.2. HCMV-Infected TBPCs Produce Infectious Progeny Virions  
To determine if TBPCs were fully permissive and produced progeny virions, the cells were infected 
with either VR1814 or AD169, conditioned medium (CM) was collected at 48 h intervals, and viral 
progeny were quantified by titration on human foreskin fibroblasts (HFFs). For comparison of virus 
yield, HFFs were infected and analyzed in parallel. We found that relatively high levels of progeny 
virions were released from infected TBPCs (total ~106 PFU per 2 cm2 plate on peak day), about 10- to 
15-fold lower than the amount released from HFFs (Figure 3A). Consistent with the comparable levels 
of IE, early and late protein expression (Figure 2A), no significant differences were found between the 
levels of VR1814 and AD169 progeny released. The results indicate that, following virion entry into 
TBPCs, both pathogenic and attenuated HCMV strains complete the lytic infectious cycle. 
Next, we determined whether viral progeny released from TBPCs retain tropism. CM harvested 
from VR1814- and AD169-infected TBPCs (8 dpi) were adsorbed to human retinal pigment epithelial 
cells (ARPE-19) or HFFs. Immunostaining for IE proteins showed that AD169 progeny failed to infect 
ARPE-19 cells (Figure 3B) whereas VR1814 progeny from infected TBPCs retained the ability to 
infect ARPE-19 and HFFs. These results suggest that progeny virions released from TBPCs in the 
infected chorion retain tropism and hence could spread to other placental cells—vCTBs, iCTBs, 
stromal fibroblasts in the villous core and endothelial cells in blood vessels—thereby promoting viral 
dissemination in utero. 
Figure 3. (A) Infected TBPCs release progeny virions. CM from VR1814- and AD169-
infected TBPCs and HFFs (MOI 0.1) were collected at the indicated time points and 
titrated on HFFs. (B) Progeny virions from TBPCs retain tropism. CM from VR1814- and 
AD169-infected TBPCs (8 dpi) was added to HFFs and ARPE-19 cells, and IE1 was 
immunostained (1 dpi). Nuclei were counterstained with DAPI. Scale bar = 200 µm. 
 
2.3. Viral Entry into TBPCs Is Independent of the Pentamer Complex 
The finding that TBPCs can be infected with AD169 suggested that the pentamer complex is not 
required for virion entry into these cells. To test this hypothesis, we performed experiments with the 
TB40/E parent virus and its UL131A-deficient mutant (ΔUL131A) [53]. The mutant has an early stop 
codon in the UL131A ORF, does not express a functional pentamer, and fails to enter epithelial and 
endothelial cells [53]. We confirmed the phenotype of parental TB40/E and ΔUL131A by infecting 




ARPE-19 cells and HFFs. As expected HFFs supported infection with both viruses as determined by 
IE protein expression at 2 dpi (Figure 4G–L), whereas ARPE-19 cells were only permissive for the 
parental virus TB40/E (Figure 4C,D), but not ΔUL131A (Figure 4E,F). To test TBPCs, we incubated 
the cells with TB40/E and ΔUL131A and found that in both cases >90% of cells expressed IE proteins 
at 2 dpi (Figure 4M–S). The results confirmed that the pentamer complex is dispensable for virion 
entry into TBPCs. These data also suggest that virion entry into TBPCs follows the pathway described 
for fibroblasts, which involves gB-mediated fusion at the plasma membrane at neutral pH [56], as 
opposed to the entry pathway into epithelial and endothelial cells, where virion uptake entails 
endocytosis [57,58]. 
Figure 4. HCMV pentamer complex is dispensable for virion entry into TBPCs. ARPE-19 
cells (A–F), HFFs (G–L) and TBPCs (M–S) were mock infected or infected (MOI 2) with 
parental TB40/E and UL131A-deficient mutant (ΔUL131A) and immunostained for IE1 
proteins (2 dpi). Nuclei were counterstained with DAPI (blue). Scale bar = 100 µm. 
 
2.4. TBPC Infection Is Blocked by mAbs to gB But Not mAbs to the Pentamer Complex 
Unlike HIG preparations, human mAbs to viral glycoproteins are epitope specific and can have 
especially high affinity. Among the important HCMV proteins that have been targeted by human 
mAbs are gB [23] and components of the pentamer complex [19]. The finding that a viral mutant 





















expresses a functional pentamer, suggested that the pentamer is dispensable for virion entry. 
Consequently, we expected that mAbs that prevent HCMV entry into a broad range of cells  
(e.g., gB-specific mAbs) would block TBPC infection, whereas mAbs to the pentamer would not. 
To test this hypothesis, we carried out neutralization assays with human mAbs to the pentamer 
component pUL130/pUL131A (mAbs 5A2 and 1F11) and a human mAb to gB (TRL345). These 
mAbs were selected by B-cell cloning and reported to have potent HCMV neutralizing titer in 
epithelial cells (anti-pUL130/pUL131A and anti-gB) and fibroblasts (anti-gB) [19,23]. First, we 
verified that the mAbs and the HIG preparation blocked VR1814 infection of ARPE-19 cells in a  
dose-dependent manner (Figure 5). The control mAb (Synagis) lacked neutralizing activity  
(Figure 5A). Next, we found that mAbs to the pentamer (mAbs 5A2 and 1F11) failed to block VR1814 
infection of TBPCs (Figure 5B), whereas anti-gB mAb TRL345 exhibited a dose-dependent 
neutralizing activity, almost completely blocking VR1814 infection (99% reduction) at 10 µg/mL 
(Figure 5B). HIG showed some neutralizing activity in TBPCs at high concentrations (~42% mean 
reduction at 10 µg/mL, ~81% at 100 µg/mL), but the efficiency was highly variable. It is difficult to 
compare HIG with HCMV neutralizing mAbs because the former is a polyclonal antibody mixture 
prepared from seropositive donors and contains mostly antibodies without antiviral activity. In 
contrast, each mAb recognizes a specific functional epitope on a single viral protein. Nonetheless,  
anti-gB mAb TRL345 blocked infection of TBPCs at 1 µg/mL to a greater extent than HIG at  
100 µg/mL. These results indicate that a mAb to gB efficiently neutralizes HCMV infection of TBPCs 
as compared with HIG.  
2.5. Neutralization of VR1814 by Anti-gB mAb TRL345 Restores TBPC Differentiation 
When cultured under differentiation conditions, TBPCs form trophospheres and express markers of 
differentiated iCTBs and STBs [27], a process that mimics early differentiation in utero. In contrast, 
infected TBPCs fail to differentiate and form trophospheres [37]. We therefore examined whether 
TRL345-mediated virus neutralization could preserve the ability of TBPCs to differentiate and form 
trophospheres. For these experiments, TBPCs were infected with VR1814 or a virus-antibody mixture 
containing 20 µg/mL anti-gB mAb (TRL345), 20 µg/mL anti-pentamer mAb (5A2) or 20 µg/mL 
negative control mAb (Synagis), or they were left uninfected. At 3 dpi, culture conditions were 
changed to induce differentiation (see Experimental Section). At 4 dpi, differentiating TBPCs 
(uninfected) formed trophospheres with diameters of approximately 200–250 µm (Figure 6A,F). In 
contrast, infected TBPCs generally failed to form spheres, and the few spheres that assembled had 
diameters of approximately 50 µm or less (Figure 6B,G). TBPCs incubated with anti-gB mAb-treated 
VR1814 retained the capacity to differentiate and formed large trophospheres (Figure 6D,I). In 
contrast, TBPCs incubated with VR1814 treated with mAbs to the pentamer or the negative  
control mAb failed to form large trophospheres (Figure 6C,E,H,J), consistent with the failure of 
pentamer-specific mAbs to block infection (Section 2.4). Thus, neutralizing anti-gB mAb TRL345 
precludes HCMV infection of TBPCs and rescues differentiation. 
  




Figure 5. Infection of TBPCs is blocked by a mAb to gB but not mAbs to the pentamer 
complex. (A) VR1814 (MOI 0.01) was pre-incubated with medium alone, a serial log10 
dilution of the indicated mAb (0.01–10 µg/mL) or HIG (0.1–100 µg/mL). Virus-antibody 
mixtures were then applied to ARPE-19 cells. At 2 dpi, IE1 was immunostained and 
numbers of infected cells were counted. Data were normalized to the no Ab control. Error 
bars indicate standard deviation. (B) TBPCs were incubated with virus-antibody mixtures 
and analyzed as described for panel A.  
 
2.6. Discussion 
The studies presented here show that HCMV undergoes lytic replication in TBPCs and that viral 
entry into these cells depends on the functions of gB but not those of the pentamer complex. 
VR1814-infected TBPCs release significant levels of progeny virions that retain epithelial cell tropism. 
These findings suggest infection of TBPCs could inhibit villous growth and differentiation and 


















































































































































































































of TBPCs (Figures 2–4) and impair differentiation (Figure 6), thereby reducing the mature trophoblast 
populations, CTBs and STBs. 
Figure 6. Neutralizing anti-gB mAb TRL345 precludes VR1814 infection and rescues 
TBPC differentiation. VR1814 was pretreated with 20 µg/mL of the indicated mAbs, and 
the mixtures were adsorbed to TBPCs. At 3 dpi, the cells were reseeded on matrigel and 
cultured in differentiation medium for 24 h followed by light microscopic analysis. Lower 
magnification photographs (upper panel), higher magnification photographs (lower panel). 
Scale bars = 200 µm. 
 
 
These findings could also explain the observation that CTBs failed to differentiate into STBs in 
cases of IUGR with congenital HCMV infection, suggesting infection and paracrine effects could 
subvert placental development [4]. Passive immunization with HIG enables compensatory growth of 
chorionic villi, increasing STB surface area and exchange [14], suggesting that neutralizing antibodies 
reduce virus replication and improve outcome. HIG was reported to prevent virus transmission to the 
placenta and fetus when administrated soon after maternal seroconversion [10–13]. In accord with 
these findings, HIG reduces viral spread in the decidua in an ex vivo tissue model [59]. Animal models 
that simulate congenital infection are rare because of the unique anatomy and biology of the 
hematogenous human placenta. However, the guinea pig has been used to measure efficacy of guinea 
pig CMV (gpCMV) antibodies in reducing transplacental infection [60]. When pregnant guinea pigs 
were infected and passively immunized with gpCMV neutralizing antiserum, fetal survival increased 
significantly, and placental inflammation and IUGR were reduced [60]. Likewise, a gpCMV gB 
subunit vaccine elicited protective neutralizing antibodies in dams, resulting in lower rates of fetal 
infection and reduced pup mortality [61]. 
HCMV entry into fibroblasts requires gB and gH/gL [46,49,50], whereas entry into epithelial  
and endothelial cells requires gB and the pentamer complex gH/gL/pUL128-131A [47–51,62]. 
Consequently, anti-gB antibodies neutralize virus entry into all cell types, whereas antibodies to the 
pentamer components pUL128, pUL130 and pUL131A selectively block infection of epithelial and 
endothelial cells [19,63]. Interestingly, antibodies to the pentamer complex are the major active 
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component of HIG [64], and delayed development of these antibodies correlates with transplacental 
transmission to the fetus [65]. Our results suggest that anti-pentamer mAbs may reduce but not prevent 
virus spread in the developing placenta, as they fail to protect TBPCs, and other cell types, including 
stromal fibroblasts from the villus core [29] and uterine smooth muscle cells (data not shown). 
Importantly, anti-gB mAbs, but not anti-pentamer mAbs, preserve the ability of TBPCs to 
differentiate. Moreover, we found that anti-gB mAb TRL345 had a higher efficiency and consistency 
as compared to HIG (Figure 5A,B). This high potency of mAb TRL345 is a consequence of the 
targeted, highly conserved AD-2 (Site I) epitope on gB [66], which the antibody binds to with high 
affinity [23]. While this neutralizing epitope is essential for gB function, it is poorly immunogenic, 
which explains why antibodies to this epitope are rare in human blood and consequently not present in 
HIG preparations [19,23,66]. HCMV infection inhibits TBPC self-renewal, proliferation and 
differentiation, which are required for proper villous development [37]. High affinity, potent human 
mAbs to gB, which functions in virion entry into a broad range of cell types, should be considered as a 
potential biotherapy for congenital HCMV infection, alone or in combination with pentamer complex 
targeting mAbs that more efficiently block infection of epithelial and endothelial cells. Additional 
advantages include a well-defined composition that reduces lot-dependent effects and increases 
consistency, suggesting mAbs could have considerable efficacy in clinical trials. 
3. Experimental Section 
3.1. Cells 
TBPCs (from 7.3 and 15.6 weeks of gestation) were established as reported [27]. Cells were grown 
on gelatin-coated plates in DMEM/F12 supplemented with 10 ng/mL basic FGF (R&D Systems, 
Minneapolis, MN, USA), 10% FCS, 10 µM SB431542 (Tocris Bioscience, Minneapolis, MN, USA), 
100 units/mL penicillin, 100 µg/mL streptomycin and 0.25 µg/mL fungizone. To exclude the presence 
of placental fibroblasts in the TBPC cultures, cells were immunostained for cytokeratin 7 (CK7), 
GATA-3 and GATA-4 as described in Section 3.3. These proteins are expressed in TBPCs but not in 
placental fibroblasts. ARPE-19 cells and HFFs were cultured in DMEM supplemented with FCS and 
penicillin/streptomycin as described previously [67,68]. 
3.2. Viruses and Infections 
VR1814 (an endothelial and epithelial cell-tropic pathogenic strain of HCMV) [69] was  
propagated in HUVEC [70], followed by a single passage in HFFs to obtain high titer stocks. AD169 
(attenuated laboratory strain), TB40/E-derived parental virus (vBAC4-luc) and ΔUL131A mutant 
(vBAC4-luc/UL131Astop) were propagated in HFFs [53]. For infection (MOI is indicated in figure 
legends), virus was diluted in DMEM, 1% FCS, 100 units/mL penicillin, 100 µg/mL streptomycin  
and adsorbed for 2 h. Virus suspensions were aspirated, cells washed with PBS and provided with  
fresh medium. 
  





Cells were fixed with 4% paraformaldehyde, permeabilized with 0.5% Triton X-100 and blocked 
with normal serum. Cells were incubated with primary antibody, followed by fluorescein 
isothiocyanate (FITC) or rhodamine red-X (RRX) labeled secondary antibodies (Jackson 
ImmunoResearch Laboratories, West Grove, PA, USA). For detection of TBPC markers, antibodies to 
cytokeratin 7 (CK7, monoclonal rat IgG, clone 7D3 [71]), GATA-3 (polyclonal goat IgG, R&D 
Systems, Minneapolis, MN, USA), GATA-4 (polyclonal goat IgG, R&D Systems) and HMGA2 
(polyclonal rabbit IgG, Abcam, Cambridge, MA, USA) were used. Murine monoclonal antibodies used 
to detect viral proteins were CH433 (anti-IE1, immediate-early protein), CH19 (anti-pp28, true-late 
protein) [72] and M23 (anti-pUL112/pUL113, early proteins) [73]. Nuclei were counterstained with 
DAPI (Sigma-Aldrich, St. Louis, MO, USA). Analyses were performed with a Nikon Eclipse TS100 
inverted fluorescence microscope equipped with a Nikon DS-F12 camera controlled by Nikon NIS 
Elements 4.0 imaging software [74]. 
3.4. Detection and Quantification of Viral Progeny 
To quantify viral progeny, TBPCs or HFFs were infected with VR1814 or AD169 (MOI 0.1). 
Conditioned media (CM) was collected every 48 h. Subsequently, virus titers in CM were determined 
with an immunofluorescence-based infectivity assay in HFFs at 24 hpi [70]. For quantification,  
at least six representative pictures were taken and IE1-positive cells counted using Fiji Image J 
software [75,76]. 
3.5. Virus Neutralization Assay 
HCMV neutralizing assays were performed as described before [36]. Briefly, TBPCs or ARPE-19 
cells were seeded in 24-well plates. Diluted mAbs (final concentration 0.01 µg/mL, 0.1 µg/mL,  
1 µg/mL or 10 µg/mL) or HIG (Cytotect, Biotest, Boca Raton, FL, USA, final concentration  
0.1 µg/mL, 1 µg/mL, 10 µg/mL or 100 µg/mL) were incubated with VR1814 (MOI 0.01, in 300 µL 
total volume) for 1 h at 37 °C with moderate agitation. Virus-antibody mixtures were adsorbed to cells 
for 2 h, followed by a wash step with PBS. The cells were then supplemented with fresh growth 
medium. At 2 dpi cells were fixed, permeabilized and immunostained for IE1 and analyzed by 
immunofluorescence microscopy (Section 3.3). IE1-positive cells were quantified as described in 
Section 3.4. Alternatively, viral titers were adjusted to give a total of 600 to 800 IE1-positive cells/well 
in 24 well plates. To target gB, human mAb TRL345 (Trellis Bioscience, LLC, South San Francisco, 
NC, USA [23]) was used. To target the pentamer, human mAb 1F11 or 5A2 (cloned from a published 
sequence [19] by Trellis Bioscience) directed to pUL130/pUL131A was used. Synagis [77], reactive 
with respiratory syncytial virus, was used as negative control mAb.  
3.6. Trophosphere Formation 
TBPCs were mock infected or infected with VR1814 or a mixture of virus and mAb as described 
above. The corresponding mAb used for pretreatment was present throughout the experiment 
(20 µg/mL). At 3 dpi, TBPCs were dissociated and reseeded in matrigel-coated plates (100,000 cells 




per 2 cm2) in differentiation medium (Knockout Serum Replacement Medium, Gibco, Grand Island, 
NE, USA) supplemented with 10% FCS, 100 units/mL penicillin, 100 µg/mL streptomycin, 
0.25 µg/mL fungizone, 10 ng/mL FGF4 (Sigma-Aldrich, St. Louis, MO, USA) and 40 ng/mL EGF 
(Invitrogen, Grand Island, NE, USA) [27]. Formation of trophospheres was analyzed by microscopy  
at 4 dpi. 
4. Conclusions 
Human TBPCs in the chorion differentiate into CTBs and STBs, the two major cell types of 
chorionic villi required for placental development. The HCMV pathogenic strain VR1814 and the 
attenuated strain AD169 replicate fully in TBPCs, and the infectious progeny released retain tropism. 
Infection is blocked by a human mAb TRL345 to gB but not mAbs to the pentamer complex. Infected 
TBPCs are functionally impaired and fail to develop into large trophospheres comprised of cells that 
express the properties of differentiated CTBs and STBs. Altogether, our results suggest that congenital 
HCMV infection could be suppressed with a broadly effective neutralizing mAb to gB to prevent 
infection of TBPCs and, together with mAbs that protect specialized placental cells, could reduce virus 
transmission at the uterine-placental interface.  
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